Expected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release

Expert Opinion on Drug Delivery

Volumn 6, Issue 3, 2009, Pages 319-331

  Pani, Luca ^a   Marchese, Giorgio ^a  

^a SARDEGNA RICERCHE   (Italy)

Author keywords

9 OH risperidone; OROS technology; Paliperidone; Pharmacokinetic; Risperidone

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CYTOCHROME P450 2D6; DOPAMINE 2 RECEPTOR; DOXAZOSIN; FLUOXETINE; GLIPIZIDE; GLYCOPROTEIN P; HYDROMORPHONE; METHYLPHENIDATE; MOOD STABILIZER; NIFEDIPINE; OXYBUTYNIN; PALIPERIDONE; PAROXETINE; PLACEBO; RISPERIDONE; VERAPAMIL; 9 HYDROXY RISPERIDONE; 9-HYDROXY-RISPERIDONE; ISOXAZOLE DERIVATIVE; NEUROLEPTIC AGENT; PYRIMIDINE DERIVATIVE;

CARDIOVASCULAR DISEASE; CHEMICAL STRUCTURE; CLINICAL FEATURE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG RESPONSE; DRUG STRUCTURE; DRUG TOLERABILITY; EMBASE; HUMAN; HYPERTENSION; MEDLINE; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OUTCOME ASSESSMENT; PROSTATE HYPERTROPHY; REVIEW; SCHIZOPHRENIA; SYSTEMATIC REVIEW; URINE INCONTINENCE; CHEMISTRY; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; HUMANS; ISOXAZOLES; PYRIMIDINES; RISPERIDONE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 66149109246     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425240902780158     Document Type: Review

References (95)

1. Beasley CM Jr, Hamilton SH, Crawford AM, et al. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol 1997;7(2):125-137 (Pubitemid 27240346)
2. Daniel DG, Zimbroff DL, Potkin SG, et al. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology 1999;20(5):491-505 (Pubitemid 29123876)
3. Emsley RA, Raniwalla J, Bailey PJ, et al. A comparison of the effects of quetiapine ('seroquel') and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. PRIZE Study Group. Int Clin Psychopharmacol 2000;15(3):121-131 (Pubitemid 30326047)
4. Kasper S. First-episode schizophrenia: the importance of early intervention and subjective tolerability. J Clin Psychiatry 1999;60(Suppl 23):5-9 (Pubitemid 30021727)
5. Lindenmayer JP, Grochowski S, Mabugat L. Clozapine effects on positive and negative symptoms: a six-month trial in treatment-refractory schizophrenics. J Clin Psychopharmacol 1994;14(3):201-204 (Pubitemid 24182187)
6. Lindström E, Eriksson B, Hellgren A, et al. Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia. Clin Ther 1995;17(3):402-412
7. Bilder RM, Goldman RS, Volavka J, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 2002;159(6):1018-1028 (Pubitemid 34586949)
8. Lublin H, Eberhard J, Levander S. Current therapy issues and unmet clinical needs in the treatment of schizophrenia: a review of the new generation antipsychotics. Int Clin Psychopharmacol 2005;20(4):183-198 (Pubitemid 40896373)
9. Csernansky JG, Schuchart EK. Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics. CNS Drugs 2002;16(7):473-484 (Pubitemid 34729151)
10. Leucht S, Barnes TR, Kissling W, et al. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 2003;160(7):1209-1222 (Pubitemid 41070936)
11. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003;60(6):553-564 (Pubitemid 36682312)
12. Meltzer HY, Mcgurk SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 1999;25(2):233-255 • An interesting study comparing the cognitive effects of several atypical antipsychotics. (Pubitemid 29272503)
13. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004;161(3):414-425 (Pubitemid 38326094)
14. Gerlach J. The continuing problem of extrapyramidal symptoms: strategies for avoidance and effective treatment. J Clin Psychiatry 1999;60(Suppl 23):20-24 (Pubitemid 30021737)
15. Leucht S, Pitschel-Walz G, Abraham D, et al. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 1999;35(1):51-68
16. Kane JM, Barrett EJ, Casey DE, et al. Metabolic effects of treatment with atypical antipsychotics. J Clin Psychiatry 2004;65(11):1447-1455
17. Nasrallah HA, Newcomer JW. Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care. J Clin Psychopharmacol 2004;24(Suppl 1):S7-14 (Pubitemid 39265949)
18. Newcomer JW. Abnormalities of glucose metabolism associated with atypical antipsychotic drugs. J Clin Psychiatry 2004;65 (Suppl 18):36-46
19. Lieberman JA, Stroup TS, McEvoy JP, et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353(12):1209-1223 • This article reports part of the results of CATIE study, providing an important overview of the clinical effects of new generation antipsychotics.
20. Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry 2007;164(3):415-427 (Pubitemid 46513155)
21. Pani L, Pira L, Marchese G. Antipsychotic efficacy: relationship to optimal D2-receptor occupancy. Eur Psychiatry 2007;22(5):267-275 • The review analyses pharmaco-kinetic and pharmaco-dynamic aspects involved in antipsychotic therapy. (Pubitemid 47096691)
22. Karlsson P, Dencker E, Nyberg S, et al. Pharmacokinetic and dopamine D2 and serotonin 5-HT2A receptor occupancy of paliperidone in healthy subjects. Eur Neuropsychopharmacol 2005;15 (Suppl 3):S385
23. WHO Drug Information 2006;20(2):100
24. Emsley R, Berwaerts J, Eerdekens M, et al. Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies. Int Clin Psychopharmacol 2008;23(6):343-356 • The study analyses the clinical effects induce by long-term administration of paliperidone ER.
25. Kramer M, Simpson G, Maciulis V, et al. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2007;27(1):6-14 (Pubitemid 46105757)
26. Davidson M, Emsley R, Kramer M, et al. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res 2007;93(1-3):117-130 • The article reports the results of one of the three 6-week placebo-controlled trials that have been carried to evaluate paliperidone ER clinical effects. (Pubitemid 46817944)
27. Kane J, Canas F, Kramer M, et al. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res 2007;90(1-3):147-161 • The article reports the results of one of the three 6-week placebo-controlled trials that have been carried to evaluate paliperidone ER clinical effects. (Pubitemid 46178537)
28. Marder SR, Kramer M, Ford L, et al. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry 2007;62(12):1363-1370 • The article reports the results of one of the three 6-week placebo-controlled trials that have been carried to evaluate paliperidone ER clinical effects. (Pubitemid 350180724)
29. Tessier C, Nuss P, Staneva G, et al. Modification of membrane heterogeneity by antipsychotic drugs: an X-ray diffraction comparative study. J Colloid Interface Sci 2008;320(2):469-475
30. Jutila A, Söderlund T, Pakkanen AL, et al. Comparison of the effects of clozapine, chlorpromazine, and haloperidol on membrane lateral heterogeneity. Chem Phys Lipids 2001;112(2):151-163 (Pubitemid 32817150)
31. Leysen JE, Janssen PM, Schotte A, et al. Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors. Psychopharmacology (Berl) 1993;112(1 Suppl):S40-54 (Pubitemid 23263249)
32. Schotte A, Bonaventure P, Janssen PF, et al. In vitro receptor binding and in vivo receptor occupancy in rat and guinea pig brain: risperidone compared with antipsychotics hitherto used. Jpn J Pharmacol 1995;69(4):399-412
33. Schotte A, Janssen PF, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 1996;124(1-2):57-73 (Pubitemid 26112775)
34. Riedel M, Schwarz MJ, Strassnig M, et al. Risperidone plasma levels, clinical response and side-effects. Eur Arch Psychiatry Clin Neurosci 2005;255(4):261-268 (Pubitemid 41187035)
35. Dremencov E, El Mansari M, Blier P. Distinct electrophysiological effects of paliperidone and risperidone on the firing activity of rat serotonin and norepinephrine neurons. Psychopharmacology (Berl) 2007;194(1):63-72 (Pubitemid 47282734)
36. Zhu HJ, Wang JS, Markowitz JS, et al. Risperidone and paliperidone inhibit p-glycoprotein activity in vitro. Neuropsychopharmacology 2007;32(4):757-764 (Pubitemid 46426181)
37. Ambudkar SV, Dey S, Hrycyna CA, et al. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999;39:361-398 (Pubitemid 29222564)
38. Uhr M, Tontsch A, Namendorf C, et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron 2008 24;57(2):203-209
39. Leschziner GD, Andrew T, Pirmohamed M, et al. ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. Pharmacogenomics J 2007;7(3):154-179 (Pubitemid 46794925)
40. Kirschbaum KM, Henken S, Hiemke C, et al. Pharmacodynamic consequences of P-glycoprotein-dependent pharmacokinetics of risperidone and haloperidol in mice. Behav Brain Res 2008;188(2):298-303
41. Xing Q, Gao R, Li H, et al. Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients. Pharmacogenomics 2006;7:987-993 (Pubitemid 44644778)
42. Wang JS, Zhu HJ, Markowitz JS, et al. Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology (Berl) 2006;187(4):415-423 (Pubitemid 44200513)
43. Nakagami T, Yasui-furukori N, Saito M, et al. Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: in vivo evidence of involvement of P-glycoprotein in risperidone disposition. Clin Pharmacol Ther 2005;78(1):43-51 (Pubitemid 40956930)
44. Vermeir M, Naessens I, Remmerie B, et al. Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans. Drug Metab Dispos 2008;36(4):769-779
45. Haefeli WE, Bargetzi MJ, Follath F, et al. Potent inhibition of cytochrome P450IID6 (debrisoquin 4-hydroxylase) by flecainide in vitro and in vivo. J Cardiovasc Pharmacol 1990;15(5):776-779 (Pubitemid 20141252)
46. Prior TI, Baker GB. Interactions between the cytochrome P450 system and the second-generation antipsychotics. J Psychiatry Neurosci 2003;28(2):99-112 (Pubitemid 36628196)
47. .Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol 2007;100(1):4-22 (Pubitemid 46051438)
48. Spina E, Avenoso A, Facciolà G, et al. Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine. Ther Drug Monit 2001;23(3):223-227 (Pubitemid 32476548)
49. Spina E, Avenoso A, Scordo MG, et al. Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction. J Clin Psychopharmacol 2002;22(4):419-423 (Pubitemid 34810333)
50. Bondolfi G, Eap CB, Bertschy G, et al. The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients. Pharmacopsychiatry 2002;35(2):50-56 (Pubitemid 34293233)
51. Ono S, Mihara K, Suzuki A, et al. Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship with CYP2D6 genotypes. Psychopharmacology (Berl) 2002;162(1):50-54 (Pubitemid 34639556)
52. Scordo MG, Spina E, Facciolà G, et al. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology (Berl) 1999;147(3):300-305 (Pubitemid 30010551)
53. Van Schaick EA, Lechat P, Remmerie BM, et al. Pharmacokinetic comparison of fast-disintegrating and conventional tablet formulations of risperidone in healthy volunteers. Clin Ther 2003;25(6):1687-1699 (Pubitemid 36801942)
54. Zhou ZL, Li X, Peng HY, et al. Multiple dose pharmacokinetics of risperidone and 9-hydroxyrisperidone in Chinese female patients with schizophrenia. Acta Pharmacol Sin 2006;27(3):381-386 (Pubitemid 43357037)
55. Conley R, Gupta SK, Sathyan G. Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form. Curr Med Res Opin 2006;22(10):1879-92 • The article provides an overview of the osmotic-controlled release oral-delivery system in clinical practice. (Pubitemid 44663390)
56. Ueng KC, Chen ZC, Yeh PS, et al. Nifedipine OROS in Chinese patients with hypertension - results of a post-marketing surveillance study in Taiwan. Blood Press Suppl 2005;1:32-38 (Pubitemid 41015711)
57. Chung M, Kourides I, Canovatchel W, et al. Pharmacokinetics and pharmacodynamics of extended-release glipizide GITS compared with immediate-release glipizide in patients with type II diabetes mellitus. J Clin Pharmacol 2002;42(6):651-657 (Pubitemid 34547448)
58. Anderson RU, Mobley D, Blank B, et al. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study Group. J Urol 1999;161(6):1809-1812 (Pubitemid 29420737)
59. Chung M, Vashi V, Puente J, et al. Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation. Br J Clin Pharmacol 1999;48(5):678-687 (Pubitemid 29520591)
60. Bass DM, Prevo M, Waxman DS. Gastrointestinal safety of an extended-release, nondeformable, oral dosage form OROS: a retrospective study. Drug Saf 2002;25(14):1021-1033 (Pubitemid 35397390)
61. Lecaillon JB, Massias P, Schoeller JP, et al. Influence of food on the absorption of metoprolol administered as an Oros drug delivery system to man. Br J Clin Pharmacol 1985;19 (Suppl 2):245S-249S (Pubitemid 16193649)
62. Kapur S, Zipursky R, Jones C, et al. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000;157(4):514-520
63. Ereshefsky L, Mascarenas CA. Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. J Clin Psychiatry 2003;64(Suppl 16):18-23 (Pubitemid 37523324)
64. Arakawa R, Ito H, Takano A, et al. Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia. Psychopharmacology (Berl) 2008;197(2):229-235
65. Meltzer HY, Bobo WV, Nuamah IF, et al. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies. J Clin Psychiatry 2008;69(5):817-829 • The article provides an evaluation of paliperidone ER clinical effects by pooling the results of three three 6-week placebo-controlled trials. (Pubitemid 351838691)
66. Schooler N, Gharabawi G, Bossie F. A "virtual" comparison of paliperidone ER and oral risperidone in patients with schizophrenia. Poster presented at 45th Annual Meeting of the American College of Neuropsychopharmacology; December 3-7, 2006; Hollywood
67. Agid O, Kapur S, Arenovich T, et al. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry 2003;60(12):1228-1235 (Pubitemid 37494076)
68. Leucht S, Busch R, Hamann J, et al. Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biol Psychiatry 2005;57(12):1543-1549 (Pubitemid 40805384)
69. Tzimos A, Samokhvalov V, Kramer M, et al. Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension. Am J Geriatr Psychiatry 2008;16(1):31-43
70. ADA.Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 2004;65:267-272
71. Matsui-sakata A, Ohtani H, Sawada Y. Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus. Drug Metab Pharmacokinet 2005;20(5):368-378
72. Baptista T, Zárate J, Joober R, et al. Drug induced weight gain, an impediment to successful pharmacotherapy: focus on antipsychotics. Curr Drug Targets 2004;5(3):279-299 (Pubitemid 38372313)
73. Buckley NA, Sanders P. Cardiovascular adverse effects of antipsychotic drugs. Drug Saf 2000;23(3):215-228 (Pubitemid 30703298)
74. Luthringer R, Staner L, Noel N, et al. A double-blind, placebo-controlled, randomized study evaluating the effect of paliperidone extended-release tablets on sleep architecture in patients with schizophrenia. Int Clin Psychopharmacol 2007;22(5):299-308 (Pubitemid 47237549)
75. Miller DD. Atypical antipsychotics: sleep, sedation, and efficacy. Prim Care Companion J Clin Psychiatry 2004;6 (Suppl 2):3-7
76. Lane HY, Liu YC, Huang CL, et al. Risperidone-related weight gain: genetic and nongenetic predictors. J Clin Psychopharmacol 2006;26(2):128-134 (Pubitemid 43740335)
77. Ellingrod VL, Miller D, Schultz SK, et al. CYP2D6 polymorphisms and atypical antipsychotic weight gain. Psychiatr Genet 2002;12(1):55-58 (Pubitemid 34274495)
78. Llerena A, Berecz R, Dorado P, et al. QTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations. J Psychopharmacol 2004;18(2):189-193 (Pubitemid 38954905)
79. Kapur S, Langlois X, Vinken P, et al. The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. J Pharmacol Exp Ther 2002;302(3):1129-1134 • The pre-clinical study provides evidence supporting the possibility that the differential blood-brain disposition may have a role in antipsychotic hyperprolactinemia induction. (Pubitemid 34920235)
80. Aravagiri M, Yuwiler A, Marder SR. Distribution after repeated oral administration of different dose levels of risperidone and 9-hydroxy-risperidone in the brain and other tissues of rat. Psychopharmacology (Berl) 1998;139(4):356-363 (Pubitemid 28435032)
81. Melkersson KI. Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite. Hum Psychopharmacol 2006;21(8):529-532 (Pubitemid 46062141)
82. Wang L, Yu L, Zhang AP, et al. Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia. J Psychopharmacol 2007;21(8):837-842 (Pubitemid 350029187)
83. Kleinberg DL, Davis JM, de Coster R, et al. Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol 1999;19(1):57-61 (Pubitemid 29047332)
84. Addington J, Addington D. Neurocognitive and social functioning in schizophrenia: a 2.5 year follow-up study. Schizophr Res 2000;44(1):47-56 (Pubitemid 30365206)
85. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996;153(3):321-330
86. Matsui M, Sumiyoshi T, Arai H, et al. Cognitive functioning related to quality of life in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2008;32(1):280-287
87. Savilla K, Kettler L, Galletly C. Relationships between cognitive deficits, symptoms and quality of life in schizophrenia. Aust N Z J Psychiatry 2008;42(6):496-504 (Pubitemid 351891128)
88. Kim SW, Shin IS, Kim JM, et al. Association between attitude toward medication and neurocognitive function in schizophrenia. Clin Neuropharmacol 2006;29(4):197-205 (Pubitemid 44510456)
89. Lambert M, Naber D. Current issues in schizophrenia: overview of patient acceptability, functioning capacity and quality of life. CNS Drugs 2004;18 (Suppl 2):5-17 (Pubitemid 38858281)
90. Harvey PD, Patterson TL, Potter LS, et al. Improvement in social competence with short-term atypical antipsychotic treatment: a randomized, double-blind comparison of quetiapine versus risperidone for social competence, social cognition, and neuropsychological functioning. Am J Psychiatry 2006;163(11):1918-1925 (Pubitemid 44807783)
91. Gefvert O, Bergström M, Långström B, et al. Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. Psychopharmacology (Berl) 1998;135(2):119-126 (Pubitemid 28055494)
92. Takano A, Suhara T, Kusumi I, et al. Time course of dopamine D2 receptor occupancy by clozapine with medium and high plasma concentrations. Prog Neuropsychopharmacol Biol Psychiatry 2006;30(1):75-81 (Pubitemid 43021324)
93. Fleischhacker WW, Rabinowitz J, Kemmler G, et al. Perceived functioning, well-being and psychiatric symptoms in patients with stable schizophrenia treated with long-acting risperidone for 1 year. Br J Psychiatry 2005;187:131-136 (Pubitemid 41139684)
94. Kahn RS, Schulz SC, Palazov VD, et al. Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007;68(6):832-842 (Pubitemid 47015481)
95. Mamo D, Kapur S, Keshavan M, et al. D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia. Neuropsychopharmacology 2008;33(2):298-304. (Pubitemid 350243350)